nicola valeri

Reader and Team Leader

Institute of Cancer Research
Country flagUnited Kingdom
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Cohort information per sample for the longitudinal metastasis cohort (Figure 4), including description of organ, timepoint sampled, tumour stage at diagnosis, whether the sample is treatment naïve, if the sample was treated in the prior interval, the number of days and months elapsing since the first timepoint, in addition to per sample genomic metrics such as PGA, number of segments, patient ploidy, per sample GD classification and overall patient GD classification.

Year:

2026

Supplementary Figures 1-17 and Figure Legends Supplementary Figure 1: CNA subclonality decreases with progression within early colorectal cancers. Supplementary Figure 2: CNA subclonality assessed by different metrics. Supplementary Figure 3: Divergence decreases with progression within early colorectal. Supplementary Figure 4: Derivation of a simple genome doubling classifier. Supplementary Figure 5: Divergence is highest in subclonal and lowest in clonal genome doubled cases. Supplementary Figure 6: In situ analysis using FISH and DNAscope shows copy number instability at the single-cell level. Supplementary Figure 7: Simulations demonstrate stabilising selection suppresses karyotypic diversity when tumours are close to fitness peak. Supplementary Figure 8: The non-identifiability of the mutation rate (μ) and the strength of stabilising selection. Supplementary Figure 9: Cross-cohort study shows CNA subclonality, CNA burden and genome doubling change with progression. Supplementary Figure 10: Multi-site longitudinal karyotype phylogenetic assessment of individual CRC patients during tumour progression and drug treatment. Supplementary Figure 11: Multi-site longitudinal karyotype assessment of individual CRC patients during tumour progression and drug treatment (patients LM001 – LM0029). Supplementary Figure 12: Multi-site longitudinal karyotype assessment of individual CRC patients during tumour progression and drug treatment (patients LM0032 – LM0089). Supplementary Figure 13: Multi-site longitudinal karyotype assessment of individual CRC patients during tumour progression and drug treatment (patients LM0095 – LM0139). Supplementary Figure 14: Number of phylogenetic copy number events and proportion of the aberrant genome subclonal correlate in carcinomas. Supplementary Figure 15: Patterns of aneuploidy evolution during metastatic spread and treatment. Supplementary Figure 16: Recurrent CNAs are similar between the primary and metastatic lesions. Supplementary Figure 17: Early colorectal cancer and primary tumour samples from metastatic patients show similar CNA recurrence and number of segments, but not PGA.

Year:

2026

Ongoing copy number alterations in model systems. A, Schematic of the method used to obtain and sequence single cells from cultured colorectal cancer cell line SW620 and patient-derived organoid (PDO) 3994-1117. Cell line SW620 underwent single-cell dispensing using the cellenONE system, followed by direct library prep (DLP) while the 10× Genomics Chromium was used to prepare single-cell libraries from the patient-derived organoid 3994-1117. B, Heatmap showing CNAs in single cells from colorectal cancer cell line SW620 and ( C ) from patient-derived organoid 3994-1117. Red = gain, blue = loss. D, Phylogenetic tree constructed using CNAs in the colorectal cancer cell line SW620. E, Frequency of copy number gains and losses at the tips of the SW620 phylogenetic tree. F, Phylogenetic tree constructed using CNAs in the colorectal cancer organoid 3994-117. G, Frequency of copy number gains and losses at the tips of the 3994-117 phylogenetic tree (as in E ).

Year:

2026

Aneuploidy increases through colorectal cancer progression, and clonal diversity decreases. A, Heatmap showing CNAs in adenomas (orange, top), early cancers (green, middle), and established cancers (blue, bottom). Thin black lines delineate cases, and within black lines are multiple regions of each case. GD status is shown on the left of the heatmap. Red = gain and blue = loss. B, PGA by adenomas, early cancers, and later-stage cancers. PGA increases through progression. C, The proportion of CNAs that are subclonal decreases through progression from adenomas to carcinomas. D, Phase space of PGA versus proportion of subclonal CNAs that are subclonal. Adenomas (orange) have low PGA but high CNA subclonality, whereas colorectal cancers (blue) have high PGA but low CNA subclonality. Early cancers (green) are more disparate in PGA and CNA subclonality. E, The proportion of CNAs that are subclonal is not significantly associated with overall survival in colorectal cancers (Kaplan–Meier analysis, groups split on the median proportion of subclonal CNAs across the cohort). F, Percentage of GD by tumor stage. GD is very rare in adenomas and more common in later stage cancers in which it is usually found to be clonal. G, The proportion of CNAs that are subclonal by tumor stage and GD status. Clonal GD is associated with a lower proportion of subclonal CNAs. ca-in-ad, cancer in adenoma.

Year:

2026

Cohort information per sample for the longitudinal metastasis cohort (Figure 4), including description of organ, timepoint sampled, tumour stage at diagnosis, whether the sample is treatment naïve, if the sample was treated in the prior interval, the number of days and months elapsing since the first timepoint, in addition to per sample genomic metrics such as PGA, number of segments, patient ploidy, per sample GD classification and overall patient GD classification.

Year:

2026

Lack of CNA heterogeneity at the level of individual colorectal cancer glands. A, (left column) Heatmaps showing CNAs in individual glands in each of six colorectal cancers. Glands were sequenced from arbitrary opposite sides of each colorectal cancer as indicated by the heatmap on the right side. Red hue colors indicate gains, and blue losses (center). Phylogenetic trees reconstructed from individual gland single-nucleotide alteration calls from exome sequenced glands. Trees are balanced (comparison with Yule model). Note, the trunk length is not shown to scale, and the number above the trunk represents the number of clonal SNVs. Branches are colored by notional tumor side where the gland was collected. HI = homoplasy index. Right, results of Bayesian inference to determine whether the observed CNA diversity is best supported by a model with or without negative selection. Model selection by deviance information criteria (DIC) suggests that the negative selection model is better supported for four patients (10 simulation replicates used for each boxplot). B, Schematic showing shape of fitness landscape used in the computational simulations of negative selection. The model parameter α determines the steepness of the single fitness peak in the landscape, at position defined by the above heatmap illustrating the optimal CNA pattern. C, Heatmaps showing CNAs of the randomly sampled glands in one simulation as function of selective strength α when the CNA rate is fixed (0.2). The simulations were based on data from patient C319, and 77 glands were sampled when the population size reached 100,000. D, Genetic divergence (top) and PGA (bottom) as a function of CNA rate and selection strength α (10 replicates for each case, the same simulation settings as in C ). Strong selection on an initially optimal clone suppresses diversity, and CNA accumulation and higher mutation rates lead to more diversity and more CNA accumulation. The box plots show the median (center), first (bottom hinge), and third (top hinge) quartiles of the data; the whiskers extend to 1.5× of the IQR (distance between the first and third quartiles); data beyond the IQR are plotted individually.

Year:

2026

Supplementary Figures 1-17 and Figure Legends Supplementary Figure 1: CNA subclonality decreases with progression within early colorectal cancers. Supplementary Figure 2: CNA subclonality assessed by different metrics. Supplementary Figure 3: Divergence decreases with progression within early colorectal. Supplementary Figure 4: Derivation of a simple genome doubling classifier. Supplementary Figure 5: Divergence is highest in subclonal and lowest in clonal genome doubled cases. Supplementary Figure 6: In situ analysis using FISH and DNAscope shows copy number instability at the single-cell level. Supplementary Figure 7: Simulations demonstrate stabilising selection suppresses karyotypic diversity when tumours are close to fitness peak. Supplementary Figure 8: The non-identifiability of the mutation rate (μ) and the strength of stabilising selection. Supplementary Figure 9: Cross-cohort study shows CNA subclonality, CNA burden and genome doubling change with progression. Supplementary Figure 10: Multi-site longitudinal karyotype phylogenetic assessment of individual CRC patients during tumour progression and drug treatment. Supplementary Figure 11: Multi-site longitudinal karyotype assessment of individual CRC patients during tumour progression and drug treatment (patients LM001 – LM0029). Supplementary Figure 12: Multi-site longitudinal karyotype assessment of individual CRC patients during tumour progression and drug treatment (patients LM0032 – LM0089). Supplementary Figure 13: Multi-site longitudinal karyotype assessment of individual CRC patients during tumour progression and drug treatment (patients LM0095 – LM0139). Supplementary Figure 14: Number of phylogenetic copy number events and proportion of the aberrant genome subclonal correlate in carcinomas. Supplementary Figure 15: Patterns of aneuploidy evolution during metastatic spread and treatment. Supplementary Figure 16: Recurrent CNAs are similar between the primary and metastatic lesions. Supplementary Figure 17: Early colorectal cancer and primary tumour samples from metastatic patients show similar CNA recurrence and number of segments, but not PGA.

Year:

2026

Stability of CNAs across space, time, tissue and treatment in colorectal cancer. A, Longitudinal assessment of CNAs in primary colorectal cancers and metachronous metastatic lesions in liver and lung showed similar CNA profiles were observed over space time, tissue and through various treatment courses. Timelines of four representative metastatic patients are shown. Schematics show the organ where cancer deposit was sampled. Genome-wide view of CNAs with gains (red) and losses (blue) relative to baseline ploidy. Proportion of Aberrant Genome Subclonal (PoAGS) and number of events are displayed for each comparison presented sequentially. To the right of each timeline is the corresponding phylogenetic tree as described in Supplementary Fig. S10. B, Mean PGA averaged across all lesions at the sampling time by time since baseline (removal of the primary colorectal cancer). The PGA remained broadly constant over time in each patient ( x -axis is days and is on a log scale). C, The pairwise difference in CNAs between regions of the primary tumors was not significantly different to the pairwise difference between regions of paired metastatic lesions. D, Across time points genetic divergence was not significantly different after treatment with various chemotherapy and/or targeted agents. E, GD was common in metastatic primary tumors and metastatic deposits and was sometimes present in some but not all of the metastatic lesions from a patient (called subclonal GD). F, An example case (LM0032) where GD was subclonal in the primary but clonal in the metastasis. The greater burden of CNAs is evident in the GD samples. G, Frequency of copy number gains (red) and losses (blue) present on the clonal branches in the set of phylogenetic trees created from the cohort. Over-representation of some CNAs is evident. H, Frequency of copy number gains and losses at the tips of the phylogenetic trees (i.e., unique events). CNAs are uniformly spread across the genome.

Year:

2026

Aneuploidy is near-ubiquitous in cancer and contributes to tumor biology. However, the temporal evolutionary dynamics that select for aneuploidy remain uncharacterized. We performed longitudinal genomic analysis of 755 samples from 167 patients with colorectal-derived neoplasias from different stages through metastasis and treatment. Adenomas had few copy number alterations (CNA) and most were subclonal, whereas cancers had many clonal CNAs, suggesting that progression goes through a CNA bottleneck. Individual colorectal cancer glands from the same tumor had similar karyotypes, despite evidence of ongoing instability at the cell level. CNAs in metastatic lesions, after therapy, and in late recurrences were similar to the primary. Mathematical modeling indicated that these data are consistent with the action of negative selection on CNAs that “trap” cancer genomes on a fitness peak characterized by specific CNAs. Hence, progression to colorectal cancer requires traversing a rugged fitness landscape, whereas subsequent CNA evolution is constrained by negative selection. Significance: We profiled 167 long-term responders longitudinally (755 samples), documenting long-term cancer evolution. We found that a genetic bottleneck is required for progression and is associated with dramatic increase in CNAs but decrease in clonal diversity. After initiation, copy number evolution is constrained by negative selection through metastasis and treatment. See related commentary by Okada et al., p. 192

Year:

2026

Epigenetic rewiring in resistant populations. A, UMAP plots for multiome samples. In the first row, different dimensionality reductions are shown: UMAP done with latent semantic index (LSI) exploiting just RNA information, LSI with just ATAC, and a combined LSI. In the second row, the combined UMAP is colored by archetypal weight. B, Clonal tree constructed using CNAs inferred from ATAC data. C, Average archetype weights. The blue barcode displays a clear difference in the ATAC profile compared with the others (gray). D and E, Average ATAC archetype weight for copy-number clones, for RNA archetypes ( D ) and ATAC archetypes ( E ). We split the tree into two major clades: The top one is more abundant in the trametinib samples, and the bottom one is more represented in the parental- and capivasertib-treated samples. The change in archetypal composition is consistent with previous observations from lentiviral lineage tracing. F and G, Average ATAC archetype weights for the violet and blue barcode in the MSI sample. H, Average ATAC archetype weights for the violet barcode in the AKT organoid under oxaliplatin treatment.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (34)

John Bridgewater

UCL Cancer Institute

UNITED KINGDOM
View details

Enric Domingo

University of Oxford

UNITED KINGDOM
View details

Giulio Caravagna

Tenure-track researcher

University of Trieste

ITALY
View details

Chris Barnes

Head of Science of AI

University College London

UNITED KINGDOM
View details

David J. Pinato

Imperial College London

UNITED KINGDOM
View details

Michael Hubank

Professor of Translational Genomics

University College London

UNITED KINGDOM
View details

Guglielmo Vetere

Assistant Professor - Gastrointestinal Medical Oncology

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Filippo Pietrantonio

Researcher (non-academic)

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Trevor A Graham

Director

Institute of Cancer Research

UNITED KINGDOM
View details

Alessio Cortellini

Imperial College London

UNITED KINGDOM
View details

Hemant M Kocher

Professor of Liver and Pancreas Surgery

Queen Mary University of London

UNITED KINGDOM
View details

Nik, Matthews

Head of the NIHR Imperial BRC Genomics Facility

Imperial College London

UNITED KINGDOM
View details

Ridwan Shaikh

Institute of Cancer Research

UNITED KINGDOM
View details

Ian Chau

Royal Marsden Hospital Sutton

UNITED KINGDOM
View details

Ann-Marie Baker

Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Michele Ghidini

Docenti di ruolo di IIa fascia

University of Insubria

ITALY
View details

Andrea Bertotti

Candiolo Cancer Institute

ITALY
View details

Luca Magnani

Docenti

University of Milan

ITALY
View details

Matteo Fassan

Docenti di ruolo di Ia fascia

University of Padova

ITALY
View details

Marco Novelli

Professor

University College London

UNITED KINGDOM
View details

Naureen Starling

Reader

Institute of Cancer Research

UNITED KINGDOM
View details

Manuel Rodriguez-Justo

Consultant & Professor Research Pathology

University College London

UNITED KINGDOM
View details

Sara Lonardi

Head of Dept

Istituto Oncologico Veneto

ITALY
View details

Ornella Garrone

Head

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

ITALY
View details

William Cross

Lecturer

University of Reading

UNITED KINGDOM
View details

Chiara Braconi

Chair in HepatoBiliary Oncology

University of Glasgow

UNITED KINGDOM
View details

Alison Berner

Clinical Senior Lecturer

Queen Mary University of London

UNITED KINGDOM
View details

Andrea Sottoriva

Head

Human Technopole

ITALY
View details

Bingxin Lu

Lecturer

University of Surrey

UNITED KINGDOM
View details

David Cunningham

Professor Cancer Medicine

Institute of Cancer Research

UNITED KINGDOM
View details

Alex Graudenzi

Tenure Track Researcher

University of Milano-Bicocca

ITALY
View details

Chiara Cremolini

University Hospital of Pisa

ITALY
View details

DANIELE GENERALI

University of Trieste

ITALY
View details

Hayley L. Belnoue-Davis

University of Oxford

UNITED KINGDOM
View details